Novo Nordisk buybacks reach DKK 11.6B since February
As of November 2, cumulative repurchases since February 4 totaled 41,714,179 B shares, with a transaction value of DKK 11,564,364,801.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Novo Nordisk A/S is repurchasing B shares under a programme for up to DKK 11,200,000,010.45 from May 6, 2026 to February 1, 2027. It forms part of an overall share repurchase programme of up to DKK 15 billion during the 12-month period beginning February 4, 2026.
After transactions through November 2, accumulated purchases under the May programme were 26,955,000 B shares, with a transaction value of DKK 7,764,364,812. Since February 4, Novo Nordisk had repurchased 41,714,179 B shares at an average DKK 277.23 per share, for a transaction value of DKK 11,564,364,801. The company held 55,754,876 B shares as treasury shares, equal to 1.2% of share capital.
Key Figures
Key Terms
Safe Harbour Rules regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 3, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 3 November 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 26 October, the following transactions have been made:
Number of B shares |
Average purchase price |
Transaction value, DKK | |
| Accumulated, last announcement | 25,515,000 | 7,387,348,112 | |
| 26 October 2026 | 240,000 | 261.38 | 62,731,559 |
| 27 October 2026 | 240,000 | 260.44 | 62,505,898 |
| 28 October 2026 | 240,000 | 257.51 | 61,801,617 |
| 29 October 2026 | 240,000 | 258.33 | 61,999,670 |
| 30 October 2026 | 240,000 | 265.96 | 63,829,371 |
| 2 November 2026 | 240,000 | 267.29 | 64,148,584 |
| Accumulated under the programme | 26,955,000 | 7,764,364,812 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 55,754,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.2% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 2 November 2026, Novo Nordisk has since 4 February 2026 repurchased a total 41,714,179 B shares at an average share price of DKK 277.23 per B share equal to a transaction value of DKK 11,564,364,801.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo -B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram , LinkedIn, TikTok, Facebook, X and YouTube.
Contacts for further information
| Novo Nordisk Media: | |
|
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Novo Nordisk Investors: | |
|
Michael Novod +45 3075 6050 nvno@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com |
Max Ung +45 3077 6414 mxun@novonordisk.com |
|
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
|
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com |
Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 64 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 3, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |